## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the present application.

## Listing of Claims

1. (currently amended) A method of treating a Pervasive Developmental Disorder selected from the group consisting of Asperger's Disorder, Rett's Disorder, Childhood Disintegrative Disorder, and Pervasive Developmental Disorder Not Otherwise Specified, comprising administering to a patient in need of such treatment an effective amount of a norepinephrine reuptake inhibitor selected from the group consisting of:

atomoxetine or a pharmaceutically acceptable salt thereof; and

~~racemic reboxetine or a pharmaceutically acceptable salt thereof;~~

~~(S,S) reboxetine or a pharmaceutically acceptable salt thereof;~~

a compound of formula (I):




(I)

wherein X is $C_1$-$C_4$ alkylthio, and Y is $C_1$-$C_2$ alkyl, or a pharmaceutically acceptable salt thereof; as sole active agent.

~~a compound of formula (IA):~~




(IA)

~~wherein n is 1, 2 or 3; R1 is $C_2$-$C_{10}$alkyl, $C_2$-$C_{10}$alkenyl, $C_3$-$C_8$cycloalkyl or $C_4$-$C_{10}$cycloalkylalkyl, wherein one C-C bond within any cycloalkyl moiety is optionally substituted by an O-C or C=C bond and wherein each group is optionally substituted with~~

~~from 1 to 7 halogen substituents and/or with from 1 to 3 substituents each independently selected from hydroxy, cyano, $C_1$-$C_4$alkyl and $C_1$-$C_4$alkoxy; R2 is H, $C_1$-$C_4$alkyl (optionally substituted with from 1 to 7 halogen atoms), $C_1$-$C_4$alkyl-$S(O)_x$- wherein x is 0, 1 or 2 (optionally substituted with from 1 to 7 halogen atoms), $C_1$-$C_4$alkoxy (optionally substituted with from 1 to 7 halogen atoms), cyano, halogen, phenyl (optionally substituted with from 1 to 3 substituents each independently selected from halogen, $C_1$-$C_4$alkyl and $C_1$-$C_4$alkoxy), phenoxy (optionally substituted with from 1 to 3 substituents each independently selected from halogen, $C_1$-$C_4$alkyl and $C_1$-$C_4$alkoxy) or -$CO_2$($C_1$-$C_4$alkyl), or together with R3 forms a further benzene ring (optionally substituted with from 1 to 3 substituents each independently selected from halogen, $C_1$-$C_4$alkyl and $C_1$-$C_4$alkoxy); R3 is H, $C_1$-$C_4$alkyl (optionally substituted with from 1 to 7 halogen atoms), $C_1$-$C_4$alkyl-$S(O)_x$- wherein x is 0, 1 or 2 (optionally substituted with from 1 to 7 halogen atoms), $C_1$-$C_4$alkoxy (optionally substituted with from 1 to 7 halogen atoms), cyano, halogen, phenyl (optionally substituted with from 1 to 3 substituents each independently selected from halogen, $C_1$-$C_4$alkyl and $C_1$-$C_4$alkoxy), phenoxy (optionally substituted with from 1 to 3 substituents each independently selected from halogen, $C_1$-$C_4$alkyl and $C_1$-$C_4$alkoxy) or -$CO_2$($C_1$-$C_4$alkyl), or together with R2 or R4 forms a further benzene ring (optionally substituted with from 1 to 3 substituents each independently selected from halogen, $C_1$-$C_4$alkyl and $C_1$-$C_4$alkoxy); R4 is H, $C_1$-$C_4$alkyl (optionally substituted with from 1 to 7 halogen atoms), $C_1$-$C_4$alkyl-$S(O)_x$- wherein x is 0, 1 or 2 (optionally substituted with from 1 to 7 halogen atoms), $C_1$-$C_4$alkoxy (optionally substituted with from 1 to 7 halogen atoms), cyano, halogen, phenyl (optionally substituted with from 1 to 3 substituents each independently selected from halogen, $C_1$-$C_4$alkyl and $C_1$-$C_4$alkoxy), phenoxy (optionally substituted with from 1 to 3 substituents each independently selected from halogen, $C_1$-$C_4$alkyl and $C_1$-$C_4$alkoxy) or -$CO_2$($C_1$-$C_4$alkyl), or together with R3 forms a further benzene ring (optionally substituted with from 1 to 3 substituents each independently selected from halogen, $C_1$-$C_4$alkyl and $C_1$-$C_4$alkoxy); R5 is H, $C_1$-$C_4$alkyl (optionally substituted with from 1 to 7 halogen atoms), $C_1$-$C_4$alkoxy (optionally substituted with from 1 to 7 halogen atoms) or halogen; R6 is H, $C_1$-$C_4$alkyl (optionally substituted with from 1 to 7 halogen atoms), $C_1$-$C_4$alkoxy (optionally substituted with from 1 to 7 halogen atoms) or halogen; R7 is H or $C_1$-$C_4$alkyl; R8 is H or $C_1$-$C_4$alkyl; R9 is H, halogen, hydroxy, cyano, $C_1$-$C_4$alkyl or $C_1$-$C_4$alkoxy; and R10 is H, halogen, hydroxy, cyano, $C_1$-$C_4$alkyl or $C_1$-$C_4$alkoxy; or a pharmaceutically acceptable salt thereof; with the proviso that the compound N-ethyl-N-benzyl-4-piperidinamine is excluded;~~

~~a compound of formula (IB):~~




~~(IB)~~

~~wherein Rx is H; Ry is H or $C_1$-$C_4$ alkyl; each Rz is independently H or $C_1$-$C_4$ alkyl; X represents O; Y represents OH or OR; R is $C_1$-$C_4$ alkyl; $Ar_1$ is a phenyl ring or a 5- or 6-membered heteroaryl ring each of which may be substituted with 1, 2, 3, 4 or 5 substituents (depending upon the number of available substitution positions) each independently selected from $C_1$-$C_4$ alkyl, O($C_1$-$C_4$ alkyl), S($C_1$-$C_4$ alkyl), halo, hydroxy, pyridyl, thiophenyl and phenyl optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from halo, $C_1$-$C_4$ alkyl, or O($C_1$-$C_4$ alkyl); and $Ar_2$ is a phenyl ring or a 5- or 6-membered heteroaryl ring each of which may be substituted with 1, 2, 3, 4 or 5 substituents (depending upon the number of available substitution positions) each independently selected from $C_1$-$C_4$ alkyl, O($C_1$-$C_4$ alkyl) and halo; wherein each above-mentioned $C_1$-$C_4$ alkyl group is optionally substituted with one or more halo atoms; or a pharmaceutically acceptable salt thereof;~~

~~a compound of formula (IC)~~




~~(IC)~~

~~wherein: A is S or O; R is H; Ar is a phenyl group optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from $C_1$-$C_4$ alkyl, O($C_1$-$C_4$ alkyl), S($C_1$-$C_4$ alkyl), halo, hydroxy, $CO_2$($C_1$-$C_4$ alkyl), pyridyl, thiophenyl and phenyl optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from halo, $C_1$-$C_4$ alkyl, or O($C_1$-$C_4$ alkyl); X is a phenyl group optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from halo, $C_1$-$C_4$ alkyl, or O($C_1$-$C_4$ alkyl); a $C_1$-$C_4$~~

~~alkyl group; a $C_3$-$C_6$-cycloalkyl group or a $CH_2$($C_3$-$C_6$-cycloalkyl) group; R' is H or $C_1$-$C_4$ alkyl; each $R^1$ is independently H or $C_1$-$C_4$-alkyl; wherein each above-mentioned $C_1$-$C_4$ alkyl group is optionally substituted with one or more halo atoms; or a pharmaceutically acceptable salt thereof; with the proviso that, when A is O, X is a $C_1$-$C_4$-alkyl group, a $C_3$-$C_6$ cycloalkyl group or a $CH_2$($C_3$-$C_6$-cycloalkyl) group;~~

~~a compound of formula (ID)~~



~~(ID)~~

~~wherein X is $C(R^4R^5)$, O or S; n is 2 or 3; $R^1$ is H or $C_1$-$C_4$-alkyl; $R^3$ is H, halo, $C_1$-$C_4$ alkyl, O($C_1$-$C_4$-alkyl), nitrile, phenyl or substituted phenyl; $R^4$ and $R^5$ are each independently selected from H or $C_1$-$C_4$-alkyl; Ar is selected from the group consisting of~~



~~in which $R^{2a}$ is H, halo, methyl or ethyl; $R^{2b}$ is H, halo or methyl; $R^{2c}$ is H, halo, methyl, trifluoromethyl, nitrile, or methoxy; $R^{2d}$ is H, halo, methyl or ethyl; $R^{2e}$ is H, halo, methyl, trifluoromethyl, nitrile, or methoxy; $R^{2f}$ is H, or fluoro; Y is O, S or $N(R^6)$; and $R^6$ is H or methyl or a pharmaceutically acceptable salt thereof;~~

~~a compound of formula (IE)~~



~~(IE)~~

~~wherein $R^1$ is $C_1$-$C_6$ alkyl (optionally substituted with 1, 2 or 3 halo substituents and/or with 1 substituent selected from S-($C_1$-$C_3$-alkyl), O-($C_1$-$C_3$-alkyl) (optionally substituted with 1, 2~~

~~or 3 F atoms), -O-($C_3$-$C_6$-cycloalkyl), -$SO_2$-($C_1$-$C_3$-alkyl), -CN, -COO-($C_1$-$C_2$-alkyl) and -OH); $C_2$-$C_6$-alkenyl; -$(CH_2)_q$-$Ar_2$; or a group of formula (i) or (ii)~~



~~(i) (ii)~~

~~$R^2$, $R^3$ and $R^4$ are each independently selected from hydrogen or $C_1$-$C_2$-alkyl; $R^5$, $R^6$, $R^7$ and $R^8$ are at each occurrence independently selected from hydrogen or $C_1$-$C_2$-alkyl; -X- is a bond, -$CH_2$-, -CH=CH-, -O-, -S-, or -$SO_2$-; -Y- is a bond, -$CH_2$- or -O-; -Z is hydrogen, -OH or -O-($C_1$-$C_3$-alkyl); p is 0, 1 or 2; q is 0, 1 or 2; r is 0 or 1; s is 0, 1, 2 or 3; t is 0, 1, 2 or 3; $Ar_1$ is phenyl, pyridyl, thiazolyl, benzothiophenyl or naphthyl; wherein said phenyl, pyridyl or thiazolyl group may be substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, $C_1$-$C_4$-alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-($C_1$-$C_4$-alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-($C_1$-$C_4$-alkyl) (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridyl, pyrazole, phenyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents); and wherein said benzothiophenyl or naphthyl group may be optionally substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, $C_1$-$C_4$-alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-($C_1$-$C_4$-alkyl) (optionally substituted with 1, 2 or 3 F atoms), and -S-($C_1$-$C_4$-alkyl) (optionally substituted with 1, 2 or 3 F atoms); $Ar_2$ is naphthyl, pyridyl, thiazolyl, furyl, thiophenyl, benzothiophenyl, or phenyl, wherein said naphthyl, pyridyl, thiazolyl, furyl, thiophenyl, benzothiophenyl, or phenyl may be substituted with 1, 2 or 3 substituents each independently selected from halo, $C_1$-$C_4$-alkyl (optionally substituted with 1, 2 or 3 F atoms) and -O-($C_1$-$C_4$-alkyl) (optionally substituted with 1, 2 or 3 F atoms); or a pharmaceutically acceptable salt thereof; provided that (a) the cyclic portion of the group of formula (i) must contain at least three carbon atoms and not more than seven ring atoms; (b) when -X- is -CH=CH-, then the cyclic portion of the group of formula (i) must contain at least five carbon atoms; and (c) when -Z is -OH or -O-($C_1$-$C_3$-alkyl), then -X- is -$CH_2$-; (d) when -Y- is -O- then p cannot be 0; and (e) the compound 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile is excluded;~~

~~a compound of formula (IF)~~



~~(IF)~~

~~wherein~~



is a group of formula (a) or (b)



~~(a)~~ ~~(b)~~

~~$R^1$ is $C_1$-$C_6$ alkyl (optionally substituted with 1, 2 or 3 halo substituents and/or with 1 substituent selected from -S-($C_1$-$C_3$ alkyl), -O-($C_1$-$C_3$ alkyl) (optionally substituted with 1, 2 or 3 F atoms), -O-($C_3$-$C_6$ cycloalkyl), $-SO_2$-($C_1$-$C_3$ alkyl), -CN, -COO-($C_1$-$C_2$ alkyl) and -OH); $C_2$-$C_6$ alkenyl; $-(CH_2)_q-Ar_2$; or a group of formula (i) or (ii)~~



~~(i)~~ ~~(ii)~~

~~$R^2$, $R^3$ and $R^4$ are each independently selected from hydrogen or $C_1$-$C_2$ alkyl; $R^5$, $R^6$, $R^7$ and $R^8$ are at each occurrence independently selected from hydrogen or $C_1$-$C_2$ alkyl; -X- is a bond, $-CH_2-$, -CH=CH-, -O-, -S-, or $-SO_2-$; -Y- is a bond, $-CH_2-$ or -O-; -Z is hydrogen, -OH or -O-($C_1$-$C_3$ alkyl); p is 0, 1 or 2; q is 0, 1 or 2; r is 0 or 1; s is 0, 1, 2 or 3; t is 0, 1, 2 or 3; $Ar_1$ is phenyl, pyridyl, thiazolyl, benzothiophenyl or naphthyl; wherein said phenyl, pyridyl or thiazolyl group may be substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, $C_1$-$C_4$ alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-($C_1$-$C_4$ alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-($C_1$-$C_4$ alkyl) (optionally substituted~~

~~with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridyl, pyrazole, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl and phenoxy (optionally substituted with 1, 2 or 3 halo substituents); and wherein said benzothiophenyl or naphthyl group may be optionally substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, $C_1$-$C_4$ alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-($C_1$-$C_4$ alkyl) (optionally substituted with 1, 2 or 3 F atoms), and -S-($C_1$-$C_4$ alkyl) (optionally substituted with 1, 2 or 3 F atoms); $Ar_2$ is naphthyl, pyridyl, thiazolyl, furyl, thiophenyl, benzothiophenyl, or phenyl, wherein said naphthyl, pyridyl, thiazolyl, furyl, thiophenyl, benzothiophenyl, or phenyl may be substituted with 1, 2 or 3 substituents each independently selected from halo, $C_1$-$C_4$ alkyl (optionally substituted with 1, 2 or 3 F atoms) and -O-($C_1$-$C_4$ alkyl) (optionally substituted with 1, 2 or 3 F atoms); or a pharmaceutically acceptable salt thereof; provided that (a) the cyclic portion of the group of formula (i) must contain at least three carbon atoms and not more than seven ring atoms; (b) when -X- is -CH=CH-, then the cyclic portion of the group of formula (i) must contain at least five carbon atoms; and (c) when -Z is -OH or -O-($C_1$-$C_3$ alkyl), then -X- is $-CH_2-$; and (d) when -Y- is -O- then p cannot be 0; and~~

~~a compound of formula (IG)~~



~~(IG)~~

~~wherein -X- is -S- or -O-; each R is independently selected from H or $C_1$-$C_4$ alkyl; $R^1$ is H, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, halo, cyano, trifluoromethyl, trifluoromethoxy, $-NR^3R^4$, $-CONR^3R^4$, $-COOR^3$ or a group of the formula (i)~~



(i)

~~$R^2$ is $C_1$-$C_4$ alkyl, phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, nitro, hydroxy, cyano, halo, trifluoromethyl,~~

~~trifluoromethoxy, benzyl, benzyloxy, $NR^6R^7$, $CONR^6R^7$, $COOR^6$, $SO_2NR^6R^7$ and $SO_2R^6$; $R^5$ is selected from $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy, carboxy, nitro, hydroxy, cyano, halo, trifluoromethyl, trifluoromethoxy, benzyl, benzyloxy, $NR^8R^9$, $CONR^8R^9$, $SO_2NR^8R^9$ and $SO_2R^8$; $R^3$, $R^4$, $R^6$, $R^7$, $R^8$ and $R^9$ are each independently selected from H or $C_1$-$C_4$ alkyl; and Z is a bond, $CH_2$, or O;~~

~~or a pharmaceutically acceptable salt thereof.~~

2. (cancelled)

3. (cancelled)

4. (currently amended) The method of claim 1 ~~or 3, or the use of claim 2 or 3~~, wherein said selective norepinehprine reuptake inhibitor is atomoxetine hydrochloride.

5. (newly added) The method of claim 1, wherein attention-deficit/hyperactivity disorder occurs comorbidly with said Pervasive Developmental Disorder.

6. (newly added) The method of claim 4, wherein attention-deficit/hyperactivity disorder occurs comorbidly with said Pervasive Developmental Disorder.